Patent ID: 8779117

Claim:
A solid pharmaceutical composition for oral administration comprising crystalline 5-azacytidine monohydrate substantially free of other solid forms of 5-azacytidine, and a pharmaceutically acceptable carrier, diluent, or excipient; wherein the composition is a capsule or a tablet, wherein the crystalline 5-azacytidine monohydrate is characterized by X-Ray Powder Diffraction peaks at the following approximate positions: 2θ Angle (degree) 6.566 11.983 13.089 15.138 17.446 20.762 21.049 22.776 24.363 25.743 26.305 28.741 31.393 32.806 33.043 33.536 36.371 39.157 41.643, and wherein the composition contains between about 5 mg and about 200 mg of 5-azacytidine.